Bayer Schering Submits Application For Registration Of Levitra In EU

Bayer Schering has submitted an application for registration of a new formulation of Levitra (vardenafil HCI) in the EU.

The company claims that in contrast to other drugs of the same class used for the treatment of erectile dysfunction, Levitra orodispersible tablet allows men a discreet and convenient intake without water, dissolving on the tongue within seconds.

The efficacy and safety of Levitra 10mg orodispersible tablet have been demonstrated in two large clinical phase III studies. The new formulation has shown in all studies the same efficacy and safety as the currently available tablet.

Jean-Philippe Milon, head of General Medicine at Bayer Schering, said: “With the submission of this new formulation of Levitra, we have reached another important strategic milestone in the development of innovative and easy-to-use men’s health products.”